Jun 27, 2022 9:15am EDT Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform
Jun 21, 2022 8:00am EDT Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting
May 23, 2022 4:10pm EDT Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study
May 12, 2022 4:10pm EDT Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results
May 05, 2022 9:15am EDT Ensysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101
Apr 20, 2022 4:05pm EDT Dr. Lynn Kirkpatrick, Invited Speaker at SMi 22nd Annual Pain Therapeutics Conference in London UK
Apr 18, 2022 4:05pm EDT Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer
Mar 31, 2022 4:05pm EDT Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results